It was a year when the company’s CEO was called to testify before Congress to defend the pricing of its EpiPen. It was a year when the company’s stock price plummeted 29%. It was a year when the company’s share of the auto-injector market fell 25%.
Yet 2016 was a year when Mylan’s chairman, Robert J Coury, received over $97 million in compensation, including a $20 million bonus and over $22 million in “transition payments” for stepping down as an officer of the company.
Last year, Mylan’s CEO, Heather Bresch, was paid $13.8 million, down 27% from the year before.
The compensation figures were disclosed Monday in a filing with the Securities and Exchange Commission.
The company is currently the subject of a class-action lawsuit by consumers alleging Mylan engaged in racketeering when it colluded with pharmacy benefit managers to keep the price of EpiPen high.
Last week, Sanofi filed suit against the Mylan alleging the company illegally blocked introduction of Auvi-Q, Sanofi’s competitor to the EpiPen.
